Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

  1. Halwani, A.S.
  2. Panizo, C.
  3. Isufi, I.
  4. Herrera, A.F.
  5. Okada, C.Y.
  6. Cull, E.H.
  7. Kis, B.
  8. Chaves, J.M.
  9. Bartlett, N.L.
  10. Ai, W.
  11. de la Cruz-Merino, L.
  12. Bryan, L.J.
  13. Houot, R.
  14. Linton, K.
  15. Briones, J.
  16. Chau, I.
  17. von Keudell, G.R.
  18. Lu, H.
  19. Yakovich, A.
  20. Chen, M.
  21. Meulen JH, T.
  22. Yurasov, S.
  23. Hsu, F.J.
  24. Flowers, C.R.
Revue:
Leukemia and Lymphoma

ISSN: 1029-2403 1042-8194

Année de publication: 2022

Volumen: 63

Número: 4

Pages: 821-833

Type: Article

DOI: 10.1080/10428194.2021.2010057 GOOGLE SCHOLAR

Objectifs de Développement Durable